Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Express Scripts, Inc. Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Our first question comes from the line of John Kreger please go ahead of William Blair. John Kreger – William Blair Hi thanks very much. George and Jeff, if you're willing to, could you just talk a bit more about your expectations for NextRx and...
- Earnings calls 2009-05-01
Additional Resources
- FDA scrutiny adds to woes at Akorn specialty drug firm; Stock plunges in wake of earnings disappointment.(Brief Article)
- Akorn Inc. has come under regulatory fire just as sales growth is slowing for the first time in years at the Buffalo Grove-based specialty drug company. In October, the U.S. Food and Drug Administration FDA cited Akorn for failing to comply with Akorn...
- Research articles 2000-11-06
- Prime Therapeutics and McKesson Corporation to Launch Specialty Pharmacy Program; PrimeRxSpecialty Offers Enhanced Patient Care and Helps Control Costs
- ST. PAUL, Minn. -- Prime Therapeutics LLC Prime has selected McKesson Corporation to facilitate the procurement and dispensing of specialty injectable and infusion therapies for its PrimeRxSpecialty program. Beginning September 1, 2004, Prime and McKesson Specialty, a subsidiary of McKesson Corporation, will work together to improve patient care and control...
- Research articles 2004-09-03
- Kmart's PayLess inks deal to buy Pay'n Save - Pay Less Drug Stores Inc
- LOS ANGELES -- In a swift, 20% expansion, Kmart's specialty drug store chain, PayLess Drug Stores, has agreed to acquire the Pay'n Save drug store chain at a fire sale price.
- Research articles 1992-06-15
- Warner Chilcott reported in $3bn deal for P&G drug unit
- NEW YORK - Warner Chilcott, a specialty drug maker, is acquiring Procter & Gamble's prescription drug business for about $3bn, the Wall Street Journal said on Sunday, citing unnamed sources. A transaction may be announced as soon as Monday, the newspaper said. The business has about $2bn of annual sales,...
- News items 2009-08-23
- Stock of Fort Lauderdale, Fla., Drug Maker Andrx Surges Sharply.(Knight Ridder/Tribune Business News)
- Mar. 23--Riding a strong recovery of biotechnology stocks, Andrx Corp. saw its shares rocket on Wednesday following a sharp falloff last week. Shares in the Fort Lauderdale drug maker jumped $11.75 to close at $103.63. "Biotechnology and specialty drug companies keep rising," said...
- Research articles 2000-03-24
- Henry Schein Inc. acquires 2 specialty drug distributors
- Health care products distributor Henry Schein Inc. (Nasdaq: HSIC) said it acquired two Chicago-based distributors of specialty pharmaceuticals.
- Research articles 2003-11-21
- AerovectRx Corp. to Present Latest in Nebulizer Drug Delivery Technology at In3 Medical Device Summit; FDA 510 Clearance Recently Granted for Novel, Efficient and Disposable Vibrating Mesh Technology
- ATLANTA -- AerovectRx Corporation, developers of new pain-free, nebulizer technology for mass-immunization and point-of care specialty drug delivery, announced that it will be presenting at the In3 Medical Device Summit Conference, Thursday, June 22, 2006, at 3:20 p.m. PT. The conference, sponsored by Medtech Insight, will be held at The...
- Research articles 2006-06-12
- Bankruptcy Risk Looms for Wilmington, N.C., Drug Maker aaiPharma.
- By Sabine Vollmer, The News & Observer, Raleigh, N.C. Knight Ridder/Tribune Business News Apr. 10--Pharmaceutical firm aaiPharma braced investors Friday for a possible bankruptcy filing as a federal grand jury broadened its investigation into the accounting practices of the specialty drug ...
- Research articles 2004-04-10
- SDM buys specialty Rx business
- TORONTO -- Shoppers Drug Mart SDM has acquired the HealthAccess specialty pharmacy business of Calea Ltd. Terms were not disclosed. The business includes distribution and dispensing, therapy management, reimbursement consulting and other manufacturer services as well as Calea's call center business, including patient and drug manufacturer support and adherence...
- Research articles 2008-08-18
- Bentley Pharmaceuticals to Present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference on April 4, 2006
- EXETER, N.H. -- Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical and drug delivery company, announced today that Fred Feldman, Ph.D., Vice President of Research and Development and Robert Stote, MD, FACP, Chief Medical Officer, will present at the CIBC Annual Biotechnology & Specialty Pharmaceuticals Conference taking place at the...
- Research articles 2006-03-16
- NYSSA Presents 9th Annual Biotech/Specialty Pharma Conference
- NEW YORK -- The New York Society of Security Analysts NYSSA will present the 9th Annual Biotech/Specialty Pharma Conference on December 14 to 15, 2005. Positive news from drug companies and a strengthening economy have given biotech and specialty pharma stocks a respectable year thus far. What does the...
- Research articles 2005-11-29
- Drug Bill Amendment Would Impact Specialty Hospitals in Wisconsin.
- By Joe Manning, Milwaukee Journal Sentinel Knight Ridder/Tribune Business News Jun. 14--A last-minute amendment to a Medicare prescription drug bill passed by the Senate Finance Committee would essentially end the practice of physicians owning specialty hospitals, a Milwaukee attorney said Friday....
- Research articles 2003-06-14
- Variability and Growth in Spending for Outpatient Specialty Pharmaceuticals
- Specialty pharmaceuticals are a unique group of drug agents used to treat complex clinical conditions. Many specialty pharmaceuticals are biological in nature and administered through injection or infusion. Tracking spending on these pharmaceuticals is complex, because these products may be processed as either medical or pharmacy claims. This study, representing...
- White papers 2005-08-01
- Drug chains: how they fared
- A special report from Drug Store News and Information Resources Inc. As every chain drug retailer knows, competition for HBA, OTC and GM dollars today is foerce and growing fiercer. Ther is seldom a day in the chain drug industry doesn't complain that mass merchandisers, food/drug combination stores,...
- Research articles 1993-12-13
- Biotech drugs beneficial but confound cost containment.(Benefits Management)
- Byline: ROBERTO CENICEROS Rapid growth in the price and availability of new specialty drug treatments is posing new challenges for employers' cost management efforts. The drugs, which typically are known as biotechnology-or biotech-drugs, are u Byline: ROBERTO CENICEROS ...
- Research articles 2004-05-03
- Three Healthcare Stories From the Week That Was
- With the week drawing to a close, here are three healthcare stories you might have overlooked: Thirteen years after House Democrat Louise Slaughter first proposed it, the Genetic Information Nondiscrimination Act, or GINA, finally passed both houses of Congress. President Bush has pledged to sign it. The...
- Blog posts 2008-04-25
- SCOLR, Inc. Reports First Quarter Financials; First Results Since Completing Transition to Specialty Pharma / Drug Delivery Company
- Business Editors/Health/Medical Writers BELLEVUE, Wash.--BUSINESS WIRE--May 18, 2004 SCOLR, Inc. (AMEX:DDD) reported today financial results for the first quarter ended March 31, 2004. As previously announced, the Company completed the sale of its probiotics business effective December 31, 2003. The results for the first quarter reflect the transition...
- Research articles 2004-05-18
- ISP Wins DEA Approval.(International Specialty Products Inc., Drug Enforcement Agency)(Brief Article)
- INTERNATIONAL SPECIALTY Products ISP has received necessary Drug Enforcement Agency approvals required to produce both Schedule I and Schedule II controlled substances. ISP will manufacture the substances at its Freetown, Mass., facility, which ISP says will be upgraded to meet cGMP requirements.
- Research articles 2001-02-05
- Specialty Laboratories Signs Agreement With Roche Diagnostics to Offer AmpliChip™ CYP450 Test; Specialty to Offer Assay for Genetic Variations That Can Influence Drug Metabolism in Patients
- VALENCIA, Calif. -- Specialty Laboratories (NYSE:SP) Specialty, a leading hospital-focused clinical reference laboratory, today announced that it has signed an agreement with Roche Diagnostics Corp. Roche to begin offering the AmpliChip CYP450 assay -- the first microarray-based test for in vitro diagnostic use.
- Research articles 2005-10-10
- << Previous
- page 1 of 1
- Next >>
